drugset / Trial / NCT04822883
Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
Non-randomizedSequentialSingle-blindTreatment
Summary
The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia
Timeline
- Start
- 2021-04-26
- Primary completion
- 2021-10-28
- Completion
- 2021-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-AMINO-3-HYDROXY-3-(PYRIDIN-4-YL)-1-(PYRROLIDIN-1-YL)PROPAN-1-ONE, (2R,3S)- | Small molecule | 10 mg | — |
| Subject | 2-AMINO-3-HYDROXY-3-(PYRIDIN-4-YL)-1-(PYRROLIDIN-1-YL)PROPAN-1-ONE, (2R,3S)- | Small molecule | 20 mg | — |
| Subject | 2-AMINO-3-HYDROXY-3-(PYRIDIN-4-YL)-1-(PYRROLIDIN-1-YL)PROPAN-1-ONE, (2R,3S)- | Small molecule | 40 mg | — |
| Subject | 2-AMINO-3-HYDROXY-3-(PYRIDIN-4-YL)-1-(PYRROLIDIN-1-YL)PROPAN-1-ONE, (2R,3S)- | Small molecule | 80 mg | — |